<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Neurologic manifestations of hyperthyroidism and Graves' disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Neurologic manifestations of hyperthyroidism and Graves' disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Neurologic manifestations of hyperthyroidism and Graves' disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Devon I Rubin, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Aminoff, MD, DSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Janet L Wilterdink, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hyperthyroidism is a common medical condition in the general population. The most common cause of hyperthyroidism is Graves' disease, but elevated thyroid hormone levels may occur due to a destructive thyroiditis, toxic adenoma or toxic multinodular goiter, or excess thyroid hormone supplementation. </p><p>Common systemic features of hyperthyroidism include palpitations, heat intolerance, and weight loss. A number of central and peripheral nervous system manifestations may also occur in patients with hyperthyroidism (<a class="graphic graphic_table graphicRef60148" href="/d/graphic/60148.html" rel="external">table 1</a>). In many cases, the neurologic manifestations occur in conjunction with the systemic features of the disease, but these may be the presenting symptom in some patients.</p><p>This topic reviews the neurologic manifestations of hyperthyroidism. Other clinical features of hyperthyroidism are discussed separately (see  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults"</a> and  <a class="medical medical_review" href="/d/html/5841.html" rel="external">"Clinical manifestations and diagnosis of Graves disease in children and adolescents"</a>). The diagnosis of hyperthyroidism is also discussed separately. (See  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H2475547580"><span class="h1">NEUROLOGIC MANIFESTATIONS OF HYPERTHYROIDISM</span></p><p class="headingAnchor" id="H2"><span class="h2">Encephalopathy</span><span class="headingEndMark"> — </span>Cognitive impairment is common in hyperthyroidism and may present as one or more different syndromes. In a cross-sectional study of older hospitalized patients, dementia and confusion were found in 33 percent and 18 percent of patients with hyperthyroidism [<a href="#rid1">1</a>]. Studies in younger individuals with newly diagnosed or induced hyperthyroidism have found lower cognitive scores compared with controls [<a href="#rid2">2</a>].</p><p>The mechanism of cognitive and behavioral dysfunction in hyperthyroidism is not known. Improvement of some clinical features (attention and concentration) with beta-blocker therapy suggests a role for a hyperthyroid-induced hyperactive adrenergic system, possibly disrupting the adrenergic pathways between the locus ceruleus and frontal lobe that subserve attention and vigilance [<a href="#rid3">3</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Patients with hyperthyroidism may experience behavioral and personality changes, such as psychosis, agitation, and depression. Less overt manifestations that are more common in less severe hyperthyroidism include anxiety, restlessness, irritability, and emotional lability [<a href="#rid4">4</a>]. Insomnia is also common. Older adult patients may have a less activated presentation with depression and lethargy, so-called apathetic thyrotoxicosis [<a href="#rid1">1</a>]. These behavioral manifestations are accompanied by cognitive impairments, particularly impaired concentration, confusion, poor orientation and immediate recall, amnesia, and constructional difficulties.</p><p></p><p class="bulletIndent1">In severe hyperthyroidism, a condition frequently referred to as "thyroid storm," seizures may accompany the encephalopathy of acute thyrotoxicosis and occasionally are the presenting clinical feature [<a href="#rid5">5</a>]. They may be focal or generalized and may include status epilepticus [<a href="#rid5">5-10</a>]. In patients with thyroid storm, the neurologic presentation is more fulminant, progressing, if untreated, through an agitated delirium to somnolence and ultimately to coma [<a href="#rid11">11</a>]. Tremor and hyperreflexia with other pyramidal tract signs are also common features of the neurologic examination [<a href="#rid12">12</a>] (see <a class="local">'Tremor'</a> below and <a class="local">'Motor neuron manifestations'</a> below). In many of these cases there is an underlying stressor, such as sepsis, trauma, or a recent surgical procedure. Other clinical features of thyroid storm, such as tachycardia, fever, and gastrointestinal symptoms, are commonly present (<a class="graphic graphic_table graphicRef60908" href="/d/graphic/60908.html" rel="external">table 2</a>). Thyroid storm is discussed separately. (See  <a class="medical medical_review" href="/d/html/7885.html" rel="external">"Thyroid storm"</a>.)</p><p></p><p class="bulletIndent1">The presentation of cognitive dysfunction in hyperthyroidism is usually acute or subacute; however, a more protracted course similar to a degenerative dementia has also been described in a handful of case reports [<a href="#rid3">3</a>]. In one patient, single-photon emission computed tomography (SPECT) demonstrated diffusely reduced cerebral uptake with an accentuation in the temporoparietal regions bilaterally, which improved following resolution of the hyperthyroid state. The possible association of subclinical hyperthyroidism and dementia risk is discussed separately. (See  <a class="medical medical_review" href="/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults", section on 'Dementia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electroencephalography </strong>– Nonspecific electroencephalography (EEG) abnormalities have been reported in 43 percent of patients with hyperthyroid encephalopathy [<a href="#rid13">13</a>]. EEG may demonstrate diffuse slowing, bitemporal sharp waves, or polyspike and slow-wave discharges, or may be normal [<a href="#rid5">5,8</a>]. In addition, an unusually high voltage with prolonged photic response and triphasic waves has been described in individual patients, but is not typical [<a href="#rid5">5,10,14</a>]. EEG may normalize with treatment, although persistence of EEG abnormalities despite a return to a euthyroid state has also been described in isolated cases, without clear prognostic implications regarding either seizure recurrence or persistence of the encephalopathy [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– Treatment of hyperthyroidism typically leads to improvement in cognitive and behavioral impairments. Agitation, inattention, and frontal lobe impairment may improve more rapidly than other cognitive functions [<a href="#rid1">1</a>]. While treatment of hyperthyroidism leads to improvement in cognitive and behavioral impairments, cognitive dysfunction may persist despite a return to a euthyroid state [<a href="#rid1">1,3</a>]. Treatment of thyroid storm and Graves' hyperthyroidism is presented separately. (See  <a class="medical medical_review" href="/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment"</a> and  <a class="medical medical_review" href="/d/html/7885.html" rel="external">"Thyroid storm"</a>.)</p><p></p><p class="bulletIndent1">Seizures in thyrotoxicosis are ultimately treated by reducing thyroid hormone concentrations; however, antiseizure medications are often used as a temporizing measure until euthyroidism is achieved. There is no evidence that any specific antiseizure medication is more effective than others in this setting [<a href="#rid10">10</a>] (see  <a class="medical medical_review" href="/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults", section on 'Management'</a>). Recurrence of both generalized tonic-clonic seizures and encephalopathy coinciding with recurrence of the hyperthyroid state has been described [<a href="#rid8">8</a>]. Unprovoked seizures are unusual, and long-term treatment with antiseizure medications is not typically required [<a href="#rid10">10</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Movement disorders</span></p><p class="headingAnchor" id="H8"><span class="h3">Tremor</span><span class="headingEndMark"> — </span>Tremor is common in patients with thyrotoxicosis. In one small series of patients with a new diagnosis of hyperthyroidism, tremor was observed in 76 percent [<a href="#rid16">16</a>].</p><p></p><p>The tremor is typically high frequency and low amplitude and is primarily seen with action. It can involve the face and head but is usually most prominent in the upper extremities [<a href="#rid17">17</a>]. It is more usual for the tremor to be incidental to other manifestations of hyperthyroidism; however, at times a disabling tremor is the presenting complaint.</p><p>The tremor of hyperthyroidism resembles an exaggerated physiologic tremor; it is indistinguishable from anxiety-associated tremor [<a href="#rid17">17</a>]. These characteristics and its responsiveness to <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> suggest that the pathogenesis is mediated by a heightened beta-adrenergic state [<a href="#rid18">18,19</a>] (see  <a class="medical medical_review" href="/d/html/4895.html" rel="external">"Overview of tremor", section on 'Physiologic tremor'</a>). Others have suggested a role for increased metabolism of dopamine in the etiology of hyperthyroid tremor.</p><p class="headingAnchor" id="H9"><span class="h3">Chorea</span><span class="headingEndMark"> — </span>Chorea is a rare complication of hyperthyroidism, occurring in less than 2 percent of patients [<a href="#rid20">20</a>]. Chorea usually occurs in the context of other features of hyperthyroidism, but it may be a presenting symptom of a thyrotoxic state. In most cases, the onset of chorea is gradual, but a sudden onset of unilateral chorea has been described [<a href="#rid21">21</a>]. Chorea may be unilateral, bilateral, or multifocal and involves the extremities predominantly and less often the trunk or facial muscles. It may be continuous or occur in paroxysms that are spontaneous or precipitated by sudden movements [<a href="#rid22">22-24</a>]. Magnetic resonance imaging (MRI) and SPECT studies are normal, with no significant structural abnormality or abnormal cerebral perfusion [<a href="#rid20">20,21</a>].</p><p>Occurring in nonautoimmune thyroid disease as well as Graves' disease, chorea is believed to represent a direct effect of hyperthyroidism on the central nervous system. Hyperthyroidism may induce a reversible functional alteration in the dopamine turnover or receptor site response to dopamine in the corpus striatum. Studies have shown a reduction in the production and turnover of the level of homovanillic acid (HVA), a metabolite of dopamine, in the cerebrospinal fluid in hyperthyroid patients [<a href="#rid25">25</a>]. This would be an expected result of an increased sensitivity of dopamine receptors and a resulting decrease in dopamine turnover.</p><p>Chorea may improve or resolve with correction of thyroid hormone levels. In some patients, this occurs rapidly; in others, it may be delayed for several weeks or more after achieving a euthyroid state [<a href="#rid26">26</a>]. Recurrence of chorea coincident with an increase in thyroid hormone levels has been reported [<a href="#rid20">20,27</a>]. Persistence of the chorea, even for decades following treatment of hyperthyroidism, has also been described [<a href="#rid28">28</a>].</p><p>In addition to reducing thyroid hormone levels, symptomatic treatment of disabling or persistent chorea may be required. Some patients may respond to beta blockers; other pharmacologic treatments of chorea are described separately. (See  <a class="medical medical_review" href="/d/html/14133.html" rel="external">"Overview of chorea", section on 'Management of chorea'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Other movement disorders</span><span class="headingEndMark"> — </span>Myoclonus occurs rarely in hyperthyroidism. Isolated cases of unusual myoclonus affecting the trunk muscles or the platysma have been reported [<a href="#rid29">29,30</a>].</p><p>Ballism accompanying chorea has also been described [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Myopathy</span><span class="headingEndMark"> — </span>Muscle weakness with or without atrophy and myalgias occurs in 60 to 80 percent of patients with untreated hyperthyroidism [<a href="#rid16">16,31,32</a>]. However, it is uncommon for a patient with hyperthyroidism to present with muscle weakness as the chief complaint. Patients with hyperthyroidism tend to develop muscle involvement more frequently after the age of 40. The likelihood of developing weakness, but not its degree, is correlated with the duration of the hyperthyroid state.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The pathogenesis of myopathy in hyperthyroidism is unknown. The rapid response to thyroid-lowering treatment, at least in some patients, and a partial improvement with <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a> suggest that the muscle dysfunction is at least partly physiologic [<a href="#rid16">16,33</a>]. Contributing features may include increased cellular metabolism and energy utilization, increased catabolism and protein degradation, and inefficient energy utilization [<a href="#rid34">34-37</a>]. A significant reduction in muscle carnitine was identified in patients with hyperthyroid myopathy compared with controls [<a href="#rid38">38</a>], and it is possible that this reduction contributes to myopathy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – As with the underlying thyroid disorder, the clinical presentation of myopathy may be acute or chronic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute thyrotoxic myopathy may present with more severe proximal and distal weakness, and rarely quadriplegia with bulbar and respiratory muscle involvement [<a href="#rid39">39,40</a>]. Rhabdomyolysis has been described in this setting [<a href="#rid41">41-43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chronic thyrotoxic myopathy is more common. Approximately two-thirds of patients with hyperthyroid myopathy report proximal weakness that usually begins several weeks to several months after the onset of hyperthyroidism. Hip flexors and quadriceps are predominantly affected [<a href="#rid16">16</a>]. The remainder usually has distal as well as proximal muscle involvement, although one series reported predominantly distal extremity weakness in 20 percent of patients [<a href="#rid44">44</a>]. The myopathy may be associated with myalgias.</p><p></p><p class="bulletIndent1">In both presentations, muscle atrophy is usually absent. However, several cases with atrophy of shoulder muscles have been described. Isolated dysphagia has also been reported [<a href="#rid39">39,45</a>]. Deep tendon reflexes are usually normal or increased, an unusual finding in a myopathic disorder, with a shortened relaxation phase [<a href="#rid16">16,44</a>]. Paresthesias due to coexisting polyneuropathy may be present. Cramps are less common than with hypothyroidism [<a href="#rid16">16</a>]. Bulbar and respiratory muscle dysfunction occurs rarely [<a href="#rid44">44,46</a>]. Weakness is sometimes the sole manifestation of the endocrinopathy [<a href="#rid32">32,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation </strong>– When a patient with hyperthyroidism presents with acute weakness or has prominent bulbar muscle involvement, myasthenia gravis (MG) is more likely than muscle disease and should be carefully ruled out in these settings. (See <a class="local">'Myasthenia gravis'</a> below.)</p><p></p><p class="bulletIndent1">Laboratory studies are unremarkable apart from abnormal thyroid function tests. Serum creatine kinase is generally normal, except in thyrotoxic crisis, but elevated aldolase occurs in approximately 30 percent of patients [<a href="#rid16">16,44</a>].</p><p></p><p class="bulletIndent1">Electromyography (EMG) may be normal but sometimes demonstrates myopathic findings of increased polyphasic, low-amplitude motor unit potentials [<a href="#rid32">32,44,47</a>]. One study found "myopathic" changes in only 10 percent of 21 patients, while 24 percent had "neuropathic" changes [<a href="#rid16">16</a>]. Spontaneous activity is atypical. Abnormal EMG has been described in hyperthyroid individuals without clinical weakness. Muscle biopsy is rarely performed, but may be normal or may show nonspecific findings. Rarely, inflammation occurs [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment of the hyperthyroid condition is usually sufficient to treat the myopathy. Symptoms may improve over a few to several months following return to euthyroid state [<a href="#rid16">16,49</a>]. Adrenergic blocking agents may be of benefit as well [<a href="#rid50">50</a>].</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Peripheral neuropathy</span></p><p class="headingAnchor" id="H2555180281"><span class="h3">Sensory polyneuropathy</span><span class="headingEndMark"> — </span>A sensory polyneuropathy may occur with hyperthyroidism. A symmetric distal sensory disturbance and reduced Achilles reflexes are the most common features. Electrodiagnostic testing with nerve conduction studies and EMG is abnormal in up to 24 percent of thyrotoxic patients and is usually consistent with an axonal pathology [<a href="#rid16">16,51-53</a>].</p><p>Treatment of hyperthyroidism with return to a euthyroid state leads to improvement of symptoms. In one small case series, resolution of sensory complaints occurred in all patients over a seven-month period [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H20"><span class="h3">Carpal tunnel syndrome</span><span class="headingEndMark"> — </span>Hyperthyroidism is an uncertain risk factor for carpal tunnel syndrome (CTS). In a prospective study of 150 patients with CTS, two patients were found with a past history of hyperthyroidism [<a href="#rid54">54</a>].</p><p>Prospective studies have identified CTS in 5 to 9 percent of patients with hyperthyroidism, although other potential contributing factors, such as diabetes, were not excluded [<a href="#rid55">55,56</a>]. This seems only marginally increased over the prevalence in the general population of 3 to 5 percent. However, the simultaneous onset of CTS symptoms and hyperthyroidism, and their remittance with treatment of hyperthyroidism, suggests a possible relationship. The pathophysiologic mechanism is not known.</p><p>The symptoms of CTS in patients with hyperthyroidism are indistinguishable from those with idiopathic CTS, with pain, sensory loss, or paresthesias in the hand in the median nerve distribution. (See  <a class="medical medical_review" href="/d/html/5288.html" rel="external">"Carpal tunnel syndrome: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H253937485"><span class="h3">Unusual neuropathies</span><span class="headingEndMark"> — </span>The term "Basedow paraplegia" has been used to describe an acute development of severe leg weakness and areflexia, which occurs in the setting of severe hyperthyroidism or thyroid storm [<a href="#rid52">52,57</a>]. The arms are usually also weak, but are less severely affected. Patients recover with treatment of hyperthyroidism. Guillain-Barré syndrome (GBS) should be considered as an alternative diagnosis in patients with this presentation; GBS has been reported to be associated with Graves' disease. (See <a class="local">'Disease associations'</a> below.)</p><p class="headingAnchor" id="H21"><span class="h2">Motor neuron manifestations</span><span class="headingEndMark"> — </span>Clinical features in patients with hyperthyroidism may include upper motor neuron signs related to pyramidal tract dysfunction as well as lower motor neuron signs related to a peripheral neuropathy, which may overlap with those of amyotrophic lateral sclerosis (ALS) [<a href="#rid51">51,52,58,59</a>]. There is no evidence of an association between hyperthyroidism and motor neuron disease [<a href="#rid60">60</a>]. </p><p>One literature review identified 19 reported cases of hyperthyroidism with clinical features of upper and lower motor neuron involvement, similar to ALS; 16 of these patients improved with treatment of hyperthyroidism [<a href="#rid61">61</a>]. In one case series of patients with hyperthyroidism, generalized hyperreflexia was seen in 38 percent of patients [<a href="#rid16">16</a>]. In rare cases, there is also corticobulbar involvement with pseudobulbar speech [<a href="#rid51">51</a>]. </p><p class="headingAnchor" id="H2863007992"><span class="h2">Thyrotoxic periodic paralysis</span><span class="headingEndMark"> — </span>Thyrotoxic periodic paralysis (PP) represents an acquired form of hypokalemic PP, in which attacks of generalized weakness occur, often precipitated by rest after strenuous exercise or a high carbohydrate load. Thyrotoxic PP is more prevalent in East Asian than in other populations and in males than in females. Any cause of hyperthyroidism can be associated with thyrotoxic PP.</p><p>This disorder is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/5154.html" rel="external">"Thyrotoxic periodic paralysis"</a>.)</p><p class="headingAnchor" id="H1545414260"><span class="h2">Headache</span><span class="headingEndMark"> — </span>Hyperthyroidism has also been shown to be associated with headaches. In two studies, hyperthyroidism was found to be more common in female patients with migraine headaches [<a href="#rid62">62,63</a>]. Additionally, several cases have been reported of patients with new-onset daily persistent headaches and newly diagnosed hyperthyroidism whose headaches remitted with treatment of the hyperthyroid state [<a href="#rid64">64-66</a>]. </p><p class="headingAnchor" id="H2042936931"><span class="h2">Seizures</span><span class="headingEndMark"> — </span>Hyperthyroidism is not generally associated with epilepsy; however, elevated thyroxine levels have also been associated with precipitating seizures in two patients with previously well-controlled juvenile myoclonic epilepsy [<a href="#rid67">67</a>].</p><p>Seizures are also a feature of the acute encephalopathy that can occur as a manifestation of thyroid storm. (See <a class="local">'Encephalopathy'</a> above.)</p><p class="headingAnchor" id="H3567895113"><span class="h1">DISEASE ASSOCIATIONS</span><span class="headingEndMark"> — </span>Certain neurologic conditions are associated with hyperthyroidism or Graves' disease but are not direct clinical manifestations of thyrotoxicosis.</p><p class="headingAnchor" id="H747468318"><span class="h2">Myasthenia gravis</span><span class="headingEndMark"> — </span>It is generally recognized that there is an association between myasthenia gravis (MG) and hyperthyroidism, particularly Graves' disease. The reported prevalence of hyperthyroidism in series of patients with MG ranges between 2 to 17 percent, compared with a 1 in 10,000 prevalence in the general population [<a href="#rid68">68-70</a>]. </p><p>The relationship between the two disorders is likely a shared autoimmune pathogenesis. Some, but not all, case series and case control studies have reported higher prevalence of antithyroid antibodies among patients with MG [<a href="#rid69">69-71</a>].</p><p>A closer association between the two disorders is also suggested by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>In 44 of 51 of patients with MG and hyperthyroidism in one series, hyperthyroidism occurred simultaneously with or prior to the development of MG [<a href="#rid68">68</a>]. More than half of the patients demonstrated parallel disease activity with worsening of both diseases over a similar period of time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The clinical manifestations of MG patients may be influenced by comorbid autoimmune thyroid disease. In one study, MG associated with autoimmune thyroid disease was found to have a higher proportion of ocular MG compared with patients with MG without thyroid disease (41 versus 21 percent), as well as a lower frequency of thymic disease (27 versus 60 percent) and acetylcholine receptor antibodies (36 versus 57 percent) [<a href="#rid72">72</a>]. The association between ocular MG and Graves' disease may reflect immunologic cross-reactivity against common autoimmune targets in the eye muscle [<a href="#rid73">73</a>]. However, in another case series, generalized MG predominated in two-thirds of 56 patients with hyperthyroidism and MG [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There may also be common genetic susceptibility in the two disorders. In one case series, all five patients with both MG and Graves' disease had in common the human leukocyte antigen (HLA) type, HLA-DQ3 [<a href="#rid74">74</a>].</p><p></p><p>Ocular MG and Graves' ophthalmopathy have overlapping symptoms but can generally be distinguished. Ptosis and orbicularis oculi weakness suggest ocular MG, while proptosis, lid retraction, lid lag, periorbital edema, and restricted eye movement with forced ductions suggest Graves' ophthalmopathy. (See  <a class="medical medical_review" href="/d/html/5242.html" rel="external">"Ocular myasthenia gravis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/7825.html" rel="external">"Clinical features and diagnosis of thyroid eye disease", section on 'Differential diagnosis'</a>.)</p><p>The treatment and prognosis of MG are similar in patients with and without hyperthyroidism and consist of acetylcholinesterase inhibitors, immunosuppressive therapy, and thymectomy [<a href="#rid69">69,75</a>]. (See  <a class="medical medical_review" href="/d/html/5157.html" rel="external">"Overview of the treatment of myasthenia gravis"</a>.)</p><p>Treatment of hyperthyroidism alone does not usually affect MG, although both improvement and worsening of MG symptoms with thyroid lowering have been described [<a href="#rid76">76,77</a>]. When the thyroid disorder is due to autoimmunity, immunosuppressive medications may lead to remission of both disorders [<a href="#rid68">68</a>]. Thymectomy appears to have no influence on hyperthyroidism. </p><p>Thymic enlargement due to hyperplasia is a common manifestation of Graves' disease and responds to its treatment. (See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults", section on 'Thymic enlargement'</a>.)</p><p class="headingAnchor" id="H3469764563"><span class="h2">Stroke</span><span class="headingEndMark"> — </span>Ischemic cerebrovascular disease is a rare complication of hyperthyroidism. In a prospective cohort study, 3176 patients aged 18 to 44 years with hyperthyroidism were followed for five years after the initial diagnosis; the cumulative incidence of ischemic stroke was 1.0 percent compared with 0.6 percent in a control group (hazard ratio [HR] 1.44, 95% CI 1.02-2.12) [<a href="#rid78">78</a>].</p><p>However, except for cardiogenic embolism in the setting of hyperthyroid-induced atrial fibrillation (AF), associations of hyperthyroidism with other stroke subtypes remain somewhat speculative. A systematic review and meta-analysis found no evidence to support an increased risk for stroke associated with subclinical hyperthyroidism (HR 1.17, 95% CI 0.87-1.34) [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H4000984299"><span class="h3">Cardiogenic embolism</span><span class="headingEndMark"> — </span>Cerebral infarction related to hyperthyroidism most commonly occurs as a result of a cardiogenic embolism in patients with hyperthyroid-induced AF [<a href="#rid80">80</a>]. AF occurs in 10 to 15 percent of individuals with hyperthyroidism and can be the presenting symptom. AF is more common in men than women, and its prevalence increases with age. Subclinical as well as overt hyperthyroidism is a risk factor for AF. However, hyperthyroidism causes a small percentage (&lt;1 percent) of AF cases. (See  <a class="medical medical_review" href="/d/html/7833.html" rel="external">"Overview of the clinical manifestations of hyperthyroidism in adults", section on 'Cardiovascular'</a>.)</p><p>Some studies suggest that stroke in the setting of thyrotoxic AF is more frequent than in nonthyrotoxic AF, but others find no difference in arterial embolism rates [<a href="#rid80">80-82</a>]. (See  <a class="medical medical_review" href="/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation", section on 'Hyperthyroidism'</a>.)</p><p>In a Korean database study of over 1 million patients with AF, patients with hyperthyroidism had a higher risk of ischemic stroke and systemic embolism than those without hyperthyroidism (1.83 versus 1.62 per 100 person-years, HR 1.13, 95% CI 1.07-1.19) [<a href="#rid83">83</a>]. This risk decreased in patients treated for hyperthyroidism (HR 0.64, 95% CI 0.58-0.70).</p><p>Anticoagulation is recommended for secondary prevention of cerebrovascular events in the setting of thyrotoxic AF. Anticoagulation is more controversial for primary prevention. This topic is discussed separately. (See  <a class="medical medical_review" href="/d/html/7853.html" rel="external">"Cardiovascular effects of hyperthyroidism", section on 'Treatment'</a> and  <a class="medical medical_review" href="/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p class="headingAnchor" id="H4020327268"><span class="h3">Cerebral venous thrombosis</span><span class="headingEndMark"> — </span>Cerebral venous thrombosis (CVT) is a rare thrombotic cerebrovascular disorder with potential for morbidity and mortality, often occurring in association with dehydration, central nervous system infection, or hypercoagulable states; approximately 25 percent of CVTs are idiopathic [<a href="#rid80">80</a>]. An association between CVT and hyperthyroidism has been suggested by reports of several patients who developed CVT simultaneously with Graves' disease and who had no other risk factors for CVT [<a href="#rid84">84-87</a>]. The number of reported cases is reported to be higher than that expected by chance alone, given the low incidence of each condition [<a href="#rid80">80,85</a>].</p><p>The mechanism of CVT in hyperthyroidism may be related to an induced hypercoagulable state, possibly from increased factor VIII clotting activity, documented in at least two cases [<a href="#rid80">80,85</a>]. In other patients, elevated plasma fibrinogen, decreased protein C activity, and increased factors IX and XI may have contributed to a thrombotic state [<a href="#rid87">87,88</a>]. Other possible contributors include altered hemodynamics or dehydration induced by hyperthyroidism, and venous stasis due to compressive effects of a thyroid goiter on cervical veins [<a href="#rid80">80,86</a>].</p><p>The clinical manifestations and diagnosis of CVT are discussed separately. (See  <a class="medical medical_review" href="/d/html/1103.html" rel="external">"Cerebral venous thrombosis: Etiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2786371943"><span class="h3">Other stroke syndromes</span><span class="headingEndMark"> — </span>Thyroid hormone may also directly affect vascular smooth muscle and endothelium and alter vascular reactivity. These changes may predispose patients to cerebrovascular complications:</p><p class="bulletIndent1"><span class="glyph">●</span>Two cases of fatal stroke and bilateral carotid artery dissection have been reported in individuals with poorly controlled Graves' disease [<a href="#rid89">89</a>]. Pathologic examination of the carotid arteries revealed a segmental mediolytic arteriopathy, an idiopathic noninflammatory vasculopathy that predisposes to dissection and aneurysm formation in cerebral and systemic blood vessels. A small case control study found that autoimmune thyroid disease (both autoimmune thyroiditis as well as Graves' disease) was associated with spontaneous carotid dissection [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Multiple intracranial stenoses, similar to those seen in moyamoya disease, have been described in several patients with Graves' disease [<a href="#rid80">80,91,92</a>]. Predominantly female, these patients had symptoms at a young age (mean 31 years). Clinical manifestations included transient ischemic attack and intracerebral hemorrhage. Proposed pathophysiologic mechanisms include an autoimmune process affecting the cerebral arteries or a vasculopathy produced by chronic thyrotoxic activation of the sympathetic nervous system [<a href="#rid91">91,93</a>]. In one series, the disease appeared to stabilize after treatment of hyperthyroidism [<a href="#rid92">92</a>]. (See  <a class="medical medical_review" href="/d/html/1131.html" rel="external">"Moyamoya disease and moyamoya syndrome: Etiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coincident autoimmune disorders may contribute to an increased risk of antiphospholipid syndrome, giant cell arteritis, antithrombin III deficiency, and Takayasu arteritis in patients with hyperthyroidism due to Graves' disease. However, as such cases are largely individually reported, an association between these disorders and Graves' disease is unproven [<a href="#rid94">94-99</a>]. One case control study did not find an association between giant cell arteritis and hyperthyroidism [<a href="#rid100">100</a>].</p><p></p><p class="headingAnchor" id="H522214357"><span class="h2">Graves' ophthalmopathy</span><span class="headingEndMark"> — </span>Graves' ophthalmopathy, an autoimmune, inflammatory disease of the retroorbital tissues, occurs in 20 to 25 percent of patients with Graves' disease. Clinical symptoms include bilateral proptosis, restricted eye movements, and periorbital edema. This topic is discussed separately. (See  <a class="medical medical_review" href="/d/html/7825.html" rel="external">"Clinical features and diagnosis of thyroid eye disease"</a> and  <a class="medical medical_review" href="/d/html/7827.html" rel="external">"Treatment of thyroid eye disease"</a>.)</p><p>In the absence of Graves' ophthalmopathy, patients may demonstrate other ophthalmic signs: widened palpebral fissures, infrequent blinking, and the appearance of lid retraction. These are believed to result from heightened sensitivity of receptors to sympathetic nervous system activity.</p><p class="headingAnchor" id="H3101516082"><span class="h2">Uncommon associations</span><span class="headingEndMark"> — </span>Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy have also been described in patients with hyperthyroidism, probably reflecting an underlying predisposition to autoimmune disease [<a href="#rid101">101,102</a>].</p><p>An enlarged thyroid gland may compress the recurrent laryngeal nerve, producing vocal cord paralysis, dysphonia, and even respiratory stridor [<a href="#rid103">103,104</a>]. A Horner syndrome may also result from compression of the sympathetic chain.</p><p>New-onset Graves' disease has been reported in 20 to 30 percent of patients treated with <a class="drug drug_general" data-topicid="8725" href="/d/drug information/8725.html" rel="external">alemtuzumab</a> for multiple sclerosis. (See  <a class="medical medical_review" href="/d/html/7845.html" rel="external">"Drug interactions with thyroid hormones", section on 'Drugs that cause hyperthyroidism'</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe hyperthyroidism</strong> – Patients with severe hyperthyroidism (thyroid storm) can present with an encephalopathy characterized by behavioral and personality changes, such as psychosis, agitation, and depression, often with seizures. These symptoms are typically accompanied by hyperpyrexia and cardiovascular dysfunction (eg, tachycardia and heart failure). (See <a class="local">'Encephalopathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other neurologic manifestations of hyperthyroidism</strong> – Other common neurologic manifestations of hyperthyroidism include tremor, hyperreflexia, and myopathy. Less common manifestations include chorea, polyneuropathy, and headache. (See <a class="local">'Tremor'</a> above and <a class="local">'Motor neuron manifestations'</a> above and <a class="local">'Myopathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management and clinical course</strong> – Treatment of hyperthyroidism typically leads to improvement in cognitive and behavioral impairments and other neurologic manifestations. Long-term treatment with antiseizure medications and other neurologic treatments are typically not required. (See  <a class="medical medical_review" href="/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment"</a> and  <a class="medical medical_review" href="/d/html/7885.html" rel="external">"Thyroid storm", section on 'Initial management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic associations with Graves' disease</strong> – Patients with Graves' disease may have a higher than expected incidence of other neurologic disorders; some (eg, myasthenia gravis [MG]) co-occur presumably because of their shared autoimmune pathogenesis. (See <a class="local">'Disease associations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Association with ischemic stroke</strong> – Ischemic stroke is associated with hyperthyroidism through a variety of mechanisms including hyperthyroid-induced atrial fibrillation (AF), a possible hypercoagulable state, and/or other autoimmune mechanisms. (See <a class="local">'Stroke'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Martin FI, Deam DR. Hyperthyroidism in elderly hospitalised patients. Clinical features and treatment outcomes. Med J Aust 1996; 164:200.</a></li><li><a class="nounderline abstract_t">Yudiarto FL, Muliadi L, Moeljanto D, Hartono B. Neuropsychological findings in hyperthyroid patients. Acta Med Indones 2006; 38:6.</a></li><li><a class="nounderline abstract_t">Fukui T, Hasegawa Y, Takenaka H. Hyperthyroid dementia: clinicoradiological findings and response to treatment. J Neurol Sci 2001; 184:81.</a></li><li><a class="nounderline abstract_t">Stern RA, Robinson B, Thorner AR, et al. A survey study of neuropsychiatric complaints in patients with Graves' disease. J Neuropsychiatry Clin Neurosci 1996; 8:181.</a></li><li><a class="nounderline abstract_t">Jabbari B, Huott AD. Seizures in thyrotoxicosis. Epilepsia 1980; 21:91.</a></li><li><a class="nounderline abstract_t">Safe AF, Griffiths KD, Maxwell RT. Thyrotoxic crisis presenting as status epilepticus. Postgrad Med J 1990; 66:150.</a></li><li><a class="nounderline abstract_t">Lee TG, Ha CK, Lim BH. Thyroid storm presenting as status epilepticus and stroke. Postgrad Med J 1997; 73:61.</a></li><li><a class="nounderline abstract_t">Li Voon Chong JS, Lecky BR, Macfarlane IA. Recurrent encephalopathy and generalised seizures associated with relapses of thyrotoxicosis. Int J Clin Pract 2000; 54:621.</a></li><li><a class="nounderline abstract_t">Aiello DP, DuPlessis AJ, Pattishall EG 3rd, Kulin HE. Thyroid storm. Presenting with coma and seizures. In a 3-year-old girl. Clin Pediatr (Phila) 1989; 28:571.</a></li><li><a class="nounderline abstract_t">Song TJ, Kim SJ, Kim GS, et al. The prevalence of thyrotoxicosis-related seizures. Thyroid 2010; 20:955.</a></li><li><a class="nounderline abstract_t">Trasciatti S, Prete C, Palummeri E, Foppiani L. Thyroid storm as precipitating factor in onset of coma in an elderly woman: case report and literature review. Aging Clin Exp Res 2004; 16:490.</a></li><li><a class="nounderline abstract_t">Newcomer J, Haire W, Hartman CR. Coma and thyrotoxicosis. Ann Neurol 1983; 14:689.</a></li><li><a class="nounderline abstract_t">SKANSE B, NYMAN GE. Thyrotoxicosis as a cause of cerebral dysrhythmia and convulsive seizures. Acta Endocrinol (Copenh) 1956; 22:246.</a></li><li><a class="nounderline abstract_t">Primavera A, Brusa G, Novello P. Thyrotoxic encephalopathy and recurrent seizures. Eur Neurol 1990; 30:186.</a></li><li><a class="nounderline abstract_t">Scott TF. Thyrotoxicosis and seizures. South Med J 1988; 81:103.</a></li><li><a class="nounderline abstract_t">Duyff RF, Van den Bosch J, Laman DM, et al. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry 2000; 68:750.</a></li><li><a class="nounderline abstract_t">Milanov I, Sheinkova G. Clinical and electromyographic examination of tremor in patients with thyrotoxicosis. Int J Clin Pract 2000; 54:364.</a></li><li><a class="nounderline abstract_t">Henderson JM, Portmann L, Van Melle G, et al. Propranolol as an adjunct therapy for hyperthyroid tremor. Eur Neurol 1997; 37:182.</a></li><li><a class="nounderline abstract_t">Kim HT, Edwards MJ, Lakshmi Narsimhan R, Bhatia KP. Hyperthyroidism exaggerating parkinsonian tremor: a clinical lesson. Parkinsonism Relat Disord 2005; 11:331.</a></li><li><a class="nounderline abstract_t">Ristić AJ, Svetel M, Dragasević N, et al. Bilateral chorea-ballism associated with hyperthyroidism. Mov Disord 2004; 19:982.</a></li><li><a class="nounderline abstract_t">Baba M, Terada A, Hishida R, et al. Persistent hemichorea associated with thyrotoxicosis. Intern Med 1992; 31:1144.</a></li><li><a class="nounderline abstract_t">Fischbeck KH, Layzer RB. Paroxysmal choreoathetosis associated with thyrotoxicosis. Ann Neurol 1979; 6:453.</a></li><li><a class="nounderline abstract_t">Yen DJ, Shan DE, Lu SR. Hyperthyroidism presenting as recurrent short paroxysmal kinesigenic dyskinesia. Mov Disord 1998; 13:361.</a></li><li><a class="nounderline abstract_t">Puri V, Chaudhry N. Paroxysmal kinesigenic dyskinesia manifestation of hyperthyroidism. Neurol India 2004; 52:102.</a></li><li><a class="nounderline abstract_t">Klawans HL Jr, Shenker DM. Observations on the dopaminergic nature of hyperthyroid chorea. J Neural Transm 1972; 33:73.</a></li><li><a class="nounderline abstract_t">Isaacs JD, Rakshi J, Baker R, et al. Chorea associated with thyroxine replacement therapy. Mov Disord 2005; 20:1656.</a></li><li><a class="nounderline abstract_t">Lucantoni C, Grottoli S, Moretti A. Chorea due to hyperthyroidism in old age. A case report. Acta Neurol (Napoli) 1994; 16:129.</a></li><li><a class="nounderline abstract_t">Javaid A, Hilton DD. Persistent chorea as a manifestation of thyrotoxicosis. Postgrad Med J 1988; 64:789.</a></li><li><a class="nounderline abstract_t">Teoh HL, Lim EC. Platysmal myoclonus in subclinical hyperthyroidism. Mov Disord 2005; 20:1064.</a></li><li><a class="nounderline abstract_t">Loh LM, Hum AY, Teoh HL, Lim EC. Graves' disease associated with spasmodic truncal flexion. Parkinsonism Relat Disord 2005; 11:117.</a></li><li><a class="nounderline abstract_t">HAVARD CW, CAMPBELL ED, ROSS HB, SPENCE AW. Electromyographic and histological findings in the muscles of patients with thyrotoxicosis. Q J Med 1963; 32:145.</a></li><li><a class="nounderline abstract_t">Ramsay ID. Electromyography in thyrotoxicosis. Q J Med 1965; 34:255.</a></li><li><a class="nounderline abstract_t">Olson BR, Klein I, Benner R, et al. Hyperthyroid myopathy and the response to treatment. Thyroid 1991; 1:137.</a></li><li><a class="nounderline abstract_t">Horak HA, Pourmand R. Endocrine myopathies. Neurol Clin 2000; 18:203.</a></li><li class="breakAll">Kaminski HJ, Ruff RL. Endocrine myopathies (hyper- and hypofunction of adrenal, thyroid, pituitary, and parathyroid glands and iatrogenic corticosteroid myopathy). In: Myology, 2nd ed, Engel AG, Franzini-Armstrong C (Eds), McGraw-Hill, New York 1994. p.1726.</li><li class="breakAll">Kissel JT, Mendell JR. The endocrine myopathies. In: Handbook of clinical neurology myopathies, Rowland LP, Dimauro S (Eds), Elsevier Science, New York 1992. p.527.</li><li><a class="nounderline abstract_t">Erkintalo M, Bendahan D, Mattéi JP, et al. Reduced metabolic efficiency of skeletal muscle energetics in hyperthyroid patients evidenced quantitatively by in vivo phosphorus-31 magnetic resonance spectroscopy. Metabolism 1998; 47:769.</a></li><li><a class="nounderline abstract_t">Sinclair C, Gilchrist JM, Hennessey JV, Kandula M. Muscle carnitine in hypo- and hyperthyroidism. Muscle Nerve 2005; 32:357.</a></li><li><a class="nounderline abstract_t">Lleó A, Sanahuja J, Serrano C, et al. Acute bulbar weakness: thyrotoxicosis or myasthenia gravis? Ann Neurol 1999; 46:434.</a></li><li><a class="nounderline abstract_t">Couillard P, Wijdicks EF. Flaccid quadriplegia due to thyrotoxic myopathy. Neurocrit Care 2014; 20:296.</a></li><li><a class="nounderline abstract_t">Lichtstein DM, Arteaga RB. Rhabdomyolysis associated with hyperthyroidism. Am J Med Sci 2006; 332:103.</a></li><li><a class="nounderline abstract_t">Alshanti M, Eledrisi MS, Jones E. Rhabdomyolysis associated with hyperthyroidism. Am J Emerg Med 2001; 19:317.</a></li><li><a class="nounderline abstract_t">Bennett WR, Huston DP. Rhabdomyolysis in thyroid storm. Am J Med 1984; 77:733.</a></li><li><a class="nounderline abstract_t">Puvanendran K, Cheah JS, Naganathan N, Wong PK. Thyrotoxic myopathy: a clinical and quantitative analytic electromyographic study. J Neurol Sci 1979; 42:441.</a></li><li><a class="nounderline abstract_t">Chiu WY, Yang CC, Huang IC, Huang TS. Dysphagia as a manifestation of thyrotoxicosis: report of three cases and literature review. Dysphagia 2004; 19:120.</a></li><li><a class="nounderline abstract_t">McElvaney GN, Wilcox PG, Fairbarn MS, et al. Respiratory muscle weakness and dyspnea in thyrotoxic patients. Am Rev Respir Dis 1990; 141:1221.</a></li><li><a class="nounderline abstract_t">Verhagen WI, Schimsheimer RJ. Neurologic disease and thyrotoxic storm. A clinical and electrophysiological study. Electromyogr Clin Neurophysiol 1986; 26:27.</a></li><li><a class="nounderline abstract_t">Hardiman O, Molloy F, Brett F, Farrell M. Inflammatory myopathy in thyrotoxicosis. Neurology 1997; 48:339.</a></li><li><a class="nounderline abstract_t">Nørrelund H, Hove KY, Brems-Dalgaard E, et al. Muscle mass and function in thyrotoxic patients before and during medical treatment. Clin Endocrinol (Oxf) 1999; 51:693.</a></li><li><a class="nounderline abstract_t">Klein I, Ojamaa K. Thyroid (neuro)myopathy. Lancet 2000; 356:614.</a></li><li><a class="nounderline abstract_t">Fisher M, Mateer JE, Ullrich I, Gutrecht JA. Pyramidal tract deficits and polyneuropathy in hyperthyroidism, Combination clinically mimicking amyotrophic lateral sclerosis. Am J Med 1985; 78:1041.</a></li><li><a class="nounderline abstract_t">Feibel JH, Campa JF. Thyrotoxic neuropathy (Basedow's paraplegia). J Neurol Neurosurg Psychiatry 1976; 39:491.</a></li><li><a class="nounderline abstract_t">Sözay S, Gökçe-Kutsal Y, Celiker R, et al. Neuroelectrophysiological evaluation of untreated hyperthyroid patients. Thyroidology 1994; 6:55.</a></li><li><a class="nounderline abstract_t">Roquer J, Cano JF. Mononeuropathies in thyrotoxicosis. J Neurol Neurosurg Psychiatry 1992; 55:332.</a></li><li><a class="nounderline abstract_t">Roquer J, Cano JF. Carpal tunnel syndrome and hyperthyroidism. A prospective study. Acta Neurol Scand 1993; 88:149.</a></li><li><a class="nounderline abstract_t">Cakir M, Samanci N, Balci N, Balci MK. Musculoskeletal manifestations in patients with thyroid disease. Clin Endocrinol (Oxf) 2003; 59:162.</a></li><li><a class="nounderline abstract_t">Pandit L, Shankar SK, Gayathri N, Pandit A. Acute thyrotoxic neuropathy--Basedow's paraplegia revisited. J Neurol Sci 1998; 155:211.</a></li><li><a class="nounderline abstract_t">RAVERA JJ, CERVINO JM, FERNANDEZ G, et al. Two cases of Graves' disease with signs of a pyramidal lesion. Improvement in neurologic signs during treatment with antithyroid drugs. J Clin Endocrinol Metab 1960; 20:876.</a></li><li><a class="nounderline abstract_t">Garcia CA, Fleming RH. Reversible corticospinal tract disease due to hyperthyroidism. Arch Neurol 1977; 34:647.</a></li><li><a class="nounderline abstract_t">Rosati G, Govoni E, Aiello I, et al. Hyperthyroidism as a precipitating factor of amyotrophic lateral sclerosis: a case report. Acta Neurol (Napoli) 1980; 2:166.</a></li><li><a class="nounderline abstract_t">Rowland LP. Diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1998; 160 Suppl 1:S6.</a></li><li><a class="nounderline abstract_t">Hagen K, Bjøro T, Zwart JA, et al. Low headache prevalence amongst women with high TSH values. Eur J Neurol 2001; 8:693.</a></li><li><a class="nounderline abstract_t">Le H, Tfelt-Hansen P, Russell MB, et al. Co-morbidity of migraine with somatic disease in a large population-based study. Cephalalgia 2011; 31:43.</a></li><li><a class="nounderline abstract_t">Herwig U, Sturzenegger M. Hyperthyroidism mimicking increased intracranial pressure. Headache 1999; 39:228.</a></li><li><a class="nounderline abstract_t">Stone J, Foulkes A, Adamson K, et al. Thyrotoxicosis presenting with headache. Cephalalgia 2007; 27:561.</a></li><li><a class="nounderline abstract_t">Evans RW, Timm JS. New Daily Persistent Headache Caused by a Multinodular Goiter and Headaches Associated With Thyroid Disease. Headache 2017; 57:285.</a></li><li><a class="nounderline abstract_t">Su YH, Izumi T, Kitsu M, Fukuyama Y. Seizure threshold in juvenile myoclonic epilepsy with Graves disease. Epilepsia 1993; 34:488.</a></li><li><a class="nounderline abstract_t">Ratanakorn D, Vejjajiva A. Long-term follow-up of myasthenia gravis patients with hyperthyroidism. Acta Neurol Scand 2002; 106:93.</a></li><li><a class="nounderline abstract_t">Weissel M, Mayr N, Zeitlhofer J. Clinical significance of autoimmune thyroid disease in myasthenia gravis. Exp Clin Endocrinol Diabetes 2000; 108:63.</a></li><li><a class="nounderline abstract_t">Kiessling WR, Pflughaupt KW, Ricker K, et al. Thyroid function and circulating antithyroid antibodies in myasthenia gravis. Neurology 1981; 31:771.</a></li><li><a class="nounderline abstract_t">Aarli JA, Thunold S, Heimann P. Thyroiditis in myasthenia gravis. Acta Neurol Scand 1978; 58:121.</a></li><li><a class="nounderline abstract_t">Marinó M, Ricciardi R, Pinchera A, et al. Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases. J Clin Endocrinol Metab 1997; 82:438.</a></li><li><a class="nounderline abstract_t">Marinò M, Barbesino G, Pinchera A, et al. Increased frequency of euthyroid ophthalmopathy in patients with Graves' disease associated with myasthenia gravis. Thyroid 2000; 10:799.</a></li><li><a class="nounderline abstract_t">Sekiguchi Y, Hara Y, Takahashi M, Hirata Y. Reverse 'see-saw' relationship between Graves' disease and myasthenia gravis; clinical and immunological studies. J Med Dent Sci 2005; 52:43.</a></li><li><a class="nounderline abstract_t">Téllez-Zenteno JF, Cardenas G, Estañol B, et al. Associated conditions in myasthenia gravis: response to thymectomy. Eur J Neurol 2004; 11:767.</a></li><li><a class="nounderline abstract_t">Hofmann WW, Denys EH. Effects of thyroid hormone at the neuromuscular junction. Am J Physiol 1972; 223:283.</a></li><li><a class="nounderline abstract_t">SAHAY BM, BLENDIS LM, GREENE R. RELATION BETWEEN MYASTHENIA GRAVIS AND THYROID DISEASE. Br Med J 1965; 1:762.</a></li><li><a class="nounderline abstract_t">Sheu JJ, Kang JH, Lin HC, Lin HC. Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study. Stroke 2010; 41:961.</a></li><li><a class="nounderline abstract_t">Chaker L, Baumgartner C, Ikram MA, et al. Subclinical thyroid dysfunction and the risk of stroke: a systematic review and meta-analysis. Eur J Epidemiol 2014; 29:791.</a></li><li><a class="nounderline abstract_t">Squizzato A, Gerdes VE, Brandjes DP, et al. Thyroid diseases and cerebrovascular disease. Stroke 2005; 36:2302.</a></li><li><a class="nounderline abstract_t">Presti CF, Hart RG. Thyrotoxicosis, atrial fibrillation, and embolism, revisited. Am Heart J 1989; 117:976.</a></li><li><a class="nounderline abstract_t">Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke 1988; 19:15.</a></li><li><a class="nounderline abstract_t">Kim K, Yang PS, Jang E, et al. Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: A nationwide cohort study. Am Heart J 2021; 242:123.</a></li><li><a class="nounderline abstract_t">Molloy E, Cahill M, O'Hare JA. Cerebral venous sinus thrombosis precipitated by Graves' disease and Factor V Leiden mutation. Ir Med J 2003; 96:46.</a></li><li><a class="nounderline abstract_t">Verberne HJ, Fliers E, Prummel MF, et al. Thyrotoxicosis as a predisposing factor for cerebral venous thrombosis. Thyroid 2000; 10:607.</a></li><li><a class="nounderline abstract_t">Siegert CE, Smelt AH, de Bruin TW. Superior sagittal sinus thrombosis and thyrotoxicosis. Possible association in two cases. Stroke 1995; 26:496.</a></li><li><a class="nounderline abstract_t">Ra CS, Lui CC, Liang CL, et al. Superior sagittal sinus thrombosis induced by thyrotoxicosis. Case report. J Neurosurg 2001; 94:130.</a></li><li><a class="nounderline abstract_t">Hwang JU, Kwon KY, Hur JW, et al. The role of hyperthyroidism as the predisposing factor for superior sagittal sinus thrombosis. J Cerebrovasc Endovasc Neurosurg 2012; 14:251.</a></li><li><a class="nounderline abstract_t">Campos CR, Basso M, Evaristo EF, et al. Bilateral carotid artery dissection with thyrotoxicosis. Neurology 2004; 63:2443.</a></li><li><a class="nounderline abstract_t">Pezzini A, Del Zotto E, Mazziotti G, et al. Thyroid autoimmunity and spontaneous cervical artery dissection. Stroke 2006; 37:2375.</a></li><li><a class="nounderline abstract_t">Nakamura K, Yanaka K, Ihara S, Nose T. Multiple intracranial arterial stenoses around the circle of Willis in association with Graves' disease: report of two cases. Neurosurgery 2003; 53:1210.</a></li><li><a class="nounderline abstract_t">Shah NH, Khandelwal P, Gordon-Perue G, et al. Acute Thyrotoxicosis of Graves Disease Associated with Moyamoya Vasculopathy and Stroke in Latin American Women: A Case Series and Review of the Literature. World Neurosurg 2016; 92:95.</a></li><li><a class="nounderline abstract_t">Tendler BE, Shoukri K, Malchoff C, et al. Concurrence of Graves' disease and dysplastic cerebral blood vessels of the moyamoya variety. Thyroid 1997; 7:625.</a></li><li><a class="nounderline abstract_t">Marongiu F, Conti M, Murtas ML, et al. Anticardiolipin antibodies in Grave's disease: relationship with thrombin activity in vivo. Thromb Res 1991; 64:745.</a></li><li><a class="nounderline abstract_t">Hofbauer LC, Spitzweg C, Heufelder AE. Graves' disease associated with the primary antiphospholipid syndrome. J Rheumatol 1996; 23:1435.</a></li><li><a class="nounderline abstract_t">Bowness P, Shotliff K, Middlemiss A, Myles AB. Prevalence of hypothyroidism in patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1991; 30:349.</a></li><li><a class="nounderline abstract_t">Thomas RD, Croft DN. Thyrotoxicosis and giant-cell arteritis. Br Med J 1974; 2:408.</a></li><li><a class="nounderline abstract_t">Kettaneh A, Prevot S, Biaggi A, et al. Hyperthyroidism in two patients with Crohn disease and Takayasu arteritis. Scand J Gastroenterol 2003; 38:901.</a></li><li><a class="nounderline abstract_t">Liu JC, Huang HY, Hsu YT. Hyperthyroidism and thrombophilia in cerebral arterial and venous thrombosis: a case report and critical review. Neurologist 2015; 19:53.</a></li><li><a class="nounderline abstract_t">Duhaut P, Bornet H, Pinède L, et al. Giant cell arteritis and thyroid dysfunction: multicentre case-control study. The Groupe de Recherche sur l'Artériteá Cellules Géantes. BMJ 1999; 318:434.</a></li><li><a class="nounderline abstract_t">Gómez R, Shetty AK, Vargas A, et al. Chronic inflammatory demyelinating polyradiculoneurophathy and Graves' disease in an adolescent with Crohn's disease. J Pediatr Gastroenterol Nutr 1999; 29:91.</a></li><li><a class="nounderline abstract_t">BRONSKY D, KAGANIEC GI, WALDSTEIN SS. AN ASSOCIATION BETWEEN THE GUILLAIN-BARR'E SYNDROME AND HYPERTHYROIDISM. Am J Med Sci 1964; 247:196.</a></li><li><a class="nounderline abstract_t">Ríos A, Rodríguez JM, Canteras M, et al. Surgical management of multinodular goiter with compression symptoms. Arch Surg 2005; 140:49.</a></li><li><a class="nounderline abstract_t">Anders HJ. Compression syndromes caused by substernal goitres. Postgrad Med J 1998; 74:327.</a></li></ol></div><div id="topicVersionRevision">Topic 4836 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8604186" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Hyperthyroidism in elderly hospitalised patients. Clinical features and treatment outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16479025" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neuropsychological findings in hyperthyroid patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231037" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hyperthyroid dementia: clinicoradiological findings and response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9081554" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A survey study of neuropsychiatric complaints in patients with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6766396" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Seizures in thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2349191" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Thyrotoxic crisis presenting as status epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039420" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Thyroid storm presenting as status epilepticus and stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11220993" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Recurrent encephalopathy and generalised seizures associated with relapses of thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2582697" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Thyroid storm. Presenting with coma and seizures. In a 3-year-old girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20718679" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The prevalence of thyrotoxicosis-related seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15739603" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Thyroid storm as precipitating factor in onset of coma in an elderly woman: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6651253" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Coma and thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13339063" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Thyrotoxicosis as a cause of cerebral dysrhythmia and convulsive seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2209671" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Thyrotoxic encephalopathy and recurrent seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336793" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Thyrotoxicosis and seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10811699" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11092109" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical and electromyographic examination of tremor in patients with thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9137929" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Propranolol as an adjunct therapy for hyperthyroid tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15970453" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hyperthyroidism exaggerating parkinsonian tremor: a clinical lesson.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15300671" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bilateral chorea-ballism associated with hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1421727" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Persistent hemichorea associated with thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/518039" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Paroxysmal choreoathetosis associated with thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9539358" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Hyperthyroidism presenting as recurrent short paroxysmal kinesigenic dyskinesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15069252" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Paroxysmal kinesigenic dyskinesia manifestation of hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4264577" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Observations on the dopaminergic nature of hyperthyroid chorea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16078207" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Chorea associated with thyroxine replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7992662" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Chorea due to hyperthyroidism in old age. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3255920" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Persistent chorea as a manifestation of thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15929096" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Platysmal myoclonus in subclinical hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15734671" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Graves' disease associated with spasmodic truncal flexion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13961061" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Electromyographic and histological findings in the muscles of patients with thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5838261" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Electromyography in thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1688015" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hyperthyroid myopathy and the response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10658176" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Endocrine myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10658176" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Endocrine myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10658176" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Endocrine myopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9667219" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Reduced metabolic efficiency of skeletal muscle energetics in hyperthyroid patients evidenced quantitatively by in vivo phosphorus-31 magnetic resonance spectroscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15803480" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Muscle carnitine in hypo- and hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10482280" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acute bulbar weakness: thyrotoxicosis or myasthenia gravis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366679" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Flaccid quadriplegia due to thyrotoxic myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16909061" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Rhabdomyolysis associated with hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11447521" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Rhabdomyolysis associated with hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6486150" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Rhabdomyolysis in thyroid storm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/512676" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Thyrotoxic myopathy: a clinical and quantitative analytic electromyographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15382800" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Dysphagia as a manifestation of thyrotoxicosis: report of three cases and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2339842" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Respiratory muscle weakness and dyspnea in thyrotoxic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3743514" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Neurologic disease and thyrotoxic storm. A clinical and electrophysiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9040717" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Inflammatory myopathy in thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619973" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Muscle mass and function in thyrotoxic patients before and during medical treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10968432" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Thyroid (neuro)myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2990204" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pyramidal tract deficits and polyneuropathy in hyperthyroidism, Combination clinically mimicking amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/932768" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Thyrotoxic neuropathy (Basedow's paraplegia).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7536451" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Neuroelectrophysiological evaluation of untreated hyperthyroid patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1316432" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Mononeuropathies in thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8213060" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Carpal tunnel syndrome and hyperthyroidism. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12864792" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Musculoskeletal manifestations in patients with thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9562270" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Acute thyrotoxic neuropathy--Basedow's paraplegia revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14436556" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Two cases of Graves' disease with signs of a pyramidal lesion. Improvement in neurologic signs during treatment with antithyroid drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/907539" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Reversible corticospinal tract disease due to hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6893385" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Hyperthyroidism as a precipitating factor of amyotrophic lateral sclerosis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9851643" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Diagnosis of amyotrophic lateral sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11784355" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Low headache prevalence amongst women with high TSH values.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20974590" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Co-morbidity of migraine with somatic disease in a large population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613219" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hyperthyroidism mimicking increased intracranial pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17598793" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Thyrotoxicosis presenting with headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28025831" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : New Daily Persistent Headache Caused by a Multinodular Goiter and Headaches Associated With Thyroid Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8504782" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Seizure threshold in juvenile myoclonic epilepsy with Graves disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100368" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Long-term follow-up of myasthenia gravis patients with hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10768835" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical significance of autoimmune thyroid disease in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6787459" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Thyroid function and circulating antithyroid antibodies in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/707039" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Thyroiditis in myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024233" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11041457" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Increased frequency of euthyroid ophthalmopathy in patients with Graves' disease associated with myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15868740" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Reverse 'see-saw' relationship between Graves' disease and myasthenia gravis; clinical and immunological studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15525299" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Associated conditions in myasthenia gravis: response to thymectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5046747" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effects of thyroid hormone at the neuromuscular junction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14248448" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : RELATION BETWEEN MYASTHENIA GRAVIS AND THYROID DISEASE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20360542" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Hyperthyroidism and risk of ischemic stroke in young adults: a 5-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25179793" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Subclinical thyroid dysfunction and the risk of stroke: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16179578" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Thyroid diseases and cerebrovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2929415" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Thyrotoxicosis, atrial fibrillation, and embolism, revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336898" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Stroke in thyrotoxicosis with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34480879" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Increased risk of ischemic stroke and systemic embolism in hyperthyroidism-related atrial fibrillation: A nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12674153" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cerebral venous sinus thrombosis precipitated by Graves' disease and Factor V Leiden mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10958314" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Thyrotoxicosis as a predisposing factor for cerebral venous thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7886732" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Superior sagittal sinus thrombosis and thyrotoxicosis. Possible association in two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11147882" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Superior sagittal sinus thrombosis induced by thyrotoxicosis. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23210057" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The role of hyperthyroidism as the predisposing factor for superior sagittal sinus thrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623728" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Bilateral carotid artery dissection with thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16888275" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Thyroid autoimmunity and spontaneous cervical artery dissection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14580289" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Multiple intracranial arterial stenoses around the circle of Willis in association with Graves' disease: report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27163552" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Acute Thyrotoxicosis of Graves Disease Associated with Moyamoya Vasculopathy and Stroke in Latin American Women: A Case Series and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292953" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Concurrence of Graves' disease and dysplastic cerebral blood vessels of the moyamoya variety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1798963" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Anticardiolipin antibodies in Grave's disease: relationship with thrombin activity in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8856626" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Graves' disease associated with the primary antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1913003" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Prevalence of hypothyroidism in patients with polymyalgia rheumatica and giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4835298" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Thyrotoxicosis and giant-cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940446" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Hyperthyroidism in two patients with Crohn disease and Takayasu arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25607334" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Hyperthyroidism and thrombophilia in cerebral arterial and venous thrombosis: a case report and critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9974458" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Giant cell arteritis and thyroid dysfunction: multicentre case-control study. The Groupe de Recherche sur l'ArtériteáCellules Géantes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10400112" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Chronic inflammatory demyelinating polyradiculoneurophathy and Graves' disease in an adolescent with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14124709" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : AN ASSOCIATION BETWEEN THE GUILLAIN-BARR'E SYNDROME AND HYPERTHYROIDISM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15655205" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Surgical management of multinodular goiter with compression symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9799884" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Compression syndromes caused by substernal goitres.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
